The Phase III CONNEX programme assessing the efficacy and safety of iclepertin in patients with schizophrenia: Trial design and recruitment update
Corey Reuteman-Fowler, Zuzana Blahova, Satoru Ikezawa, Steve Marder et autres
Introduction In a 12-week, Phase II (NCT02832037) trial, iclepertin (BI 425809), an inhibitor of glycine transporter-1, was generally well tolerated and significantly improved cognition in 509 patients with schizophrenia. Objectives The Phase III CONNEX programme aims to confirm the efficacy, safety and …
fr, at, jp, us, de (code pays fourni par la source)
2 citations
European Psychiatry